HIV vaccine trials in Africa

AIDS

Volumn 16, Issue SUPPL. 4, 2002, Pages

  Sandström, Eric ^a   Birx, Deborah ^b  

^a STOCKHOLM SÖDER HOSPITAL   (Sweden)

^b WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

Author keywords

Africa; HIV; Vaccine trials

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS VACCINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; AFRICA; CLINICAL RESEARCH; CLINICAL TRIAL; FINANCIAL MANAGEMENT; GOVERNMENT; HEALTH CARE ORGANIZATION; HEALTH EDUCATION; HEALTH PROGRAM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; MODEL; PRIORITY JOURNAL; REVIEW; THAILAND; UGANDA; VACCINATION; VIRUS TRANSMISSION;

AIDS VACCINES; CLINICAL TRIALS, PHASE III; COOPERATIVE BEHAVIOR; DEVELOPING COUNTRIES; HIV INFECTIONS; HIV-1; HUMANS;

EID: 0037004639     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200216004-00013     Document Type: Review

References (27)

1. UNAIDS. AIDS epidemic update: December 2000. Geneva: UNAIDS/WHO December, 2000.
2. http://www.unaids.org/barcelona/presskit/report.html
3. Willbond P, Thottingal P, Kimani J, et al. The Evidence base of interventions in the care and management of AIDS in low and middle income countries. Commission on Macroeconomics and Health Working Paper Series. Paper No. WG5: 25.
4. Barnhart HX, Caldwell MB, Thomas P. Natural history of human immunodeficiency virus disease in perinatally infected children: an analysis from the Pediatric Spectrum of Disease Project. Pediatrics 1996, 97:710-716.
5. The Voluntary HIV-1 Counseling and Testing Efficacy Study Group. Efficacy of voluntary HIV-1 counseling and testing in individuals and couples in Kenya, Tanzania, and Trinidad: a randomized trial. Lancet 2000, 356:103-112.
6. World Bank. Confronting AIDS: Public Priorities in a Global Epidemic. Washington: Oxford University Press; 1997.
7. http://www.iavi.org/trials/basicresearchform.asp
8. Djomand G, Sasson-Maroko M. Virologic and immunologic response to antiretroviral therapy among patients participating in the UNAIDS/Ministry of Health initial to improve access to therapy for HIV-1 infected persons on Coted'Ivoire. XIII International Conference on AIDS, Durban, South Africa. Oral Presentation, TuOrB295, Durban, South Africa.
9. UNAIDS. Ethical considerations in HIV preventive vaccine research. UNAIDS guidance document.
10. http://www.unaids.org/publications/documents/vaccines/vaccines/ JC765-EthicalCons-Repr-E.pdf
11. African AIDS Vaccine Programme at http://www.who.int/HIV-vaccines/Documents/Forum_proceedings/index.htm
12. African AIDS Vaccine Programme, The Nairobi Declaration at http://www.mrc.ac.za/mrcnews/dec2000/nairobi.htm
13. Robinson HL. New hope for an AIDS vaccine. Nature Rev 2002, 2:239-250.
14. Kimani J, Kariri T, Plummer FA, et al. Access to antiretroviral therapy in Kenya. Report to UNICEF and EASO, January 2001.
15. Barnhart HX, Caldwell MB, Thomas P. Natural history of human immunodeficiency virus disease in perinatally infected children: an analysis from the Pediatric Spectrum of Disease Project. Pediatrics 1996, 97:710-716.
16. French N, Mujugira A, Nakiyingi J, et al. Immunologic and clinical stages in HIV-1 infected Ugandan adults are comparable and provide no evidence of rapid progression but poor survival with advance disease. J Acquir Immune Defic Syndr 1999, 22:509-516.
17. Morgan D, Maude GH, Malamba SS, et al. HIV-1 disease progression and AIDS-defining disorders in rural Uganda. Lancet 1997, 350:245-250.
18. Esparza J, Osmanov S, Pattoux-Markovic C, et al. Past, present and future of HIV vaccine trials in developing countries. Vaccine 2002, 20:1897-1898.
19. Mugyenyi PN. HIV vaccines: the Uganda experience. Vaccine 2002, 20:1905-1908.
20. Ochola D, Weidle P, Malamba S, Muyingo S. Uganda Ministry of Health - UNAIDS HIV/AIDS Drug Access Initiative -Preliminary Report August 1998 - March 2000.
21. Kaplan JE, Hu DJ, Holmes KK, et al. Preventing opportunistic infections in human immunodeficiency virus-infected persons: implications for the developing world. Am J Trop Med Hyg 1996, 55:1-11.
22. Gilks CF. Prophylaxis for HIV-associated infections in the developing world. J Antimicrob Chemother 1993, 31:119-128.
23. Mansergh G, Haddix AC, Steketee RW, Simonds RJ. Cost-effectiveness of zidovudine to prevent mother-to-child transmission of HIV in sub-Saharan Africa. JAMA 1998, 280:30-31.
24. Marseille E, Kahn JG, Mmiro F, et al. Cost effectiveness of single-dose nevirapine regimen for mothers and babies to decrease vertical HIV-1 transmission in sub-Saharan Africa. Lancet 1999, 354:803-809.
25. Wood E, Braitstein P, Montaner JS, et al. Extent to which low-level use of antiretroviral treatment could curb the AIDS epidemic in sub-Saharan Africa. Lancet 2000, 355:2095-2100.
26. Ravera M, Reggiori A, Agliata AM, Rocco RP. Evaluating diagnosis and treatment of oral and esophageal candidiasis in Ugandan AIDS patients. Emerg Infect Dis 1999, 5:274-277.
27. Johnston MI, Flores J. Progress in HIV vaccine development. Curr Opin Pharmacology 2001, 1:504-510